Claims for Patent: 10,239,948

Summary for Patent: 10,239,948

Title:	Method of engineering multi-input signal sensitive T cell for immunotherapy
Abstract:	The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals. The invention also relates to new designed chimeric antigen receptors which are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties and the hypoxia condition. The present invention also relates to cells obtained by the present method, in particular T-cells, comprising said chimeric antigen receptors for use in cancer treatments.
Inventor(s):	Juillerat; Alexandre (New York, NY), Bertonati; Claudia (Saint Louis, FR), Valton; Julien (New York, NY), Duchateau; Philippe (Draveil, FR), Poirot; Laurent (Paris, FR)
Assignee:	CELLECTIS (Paris, FR)
Application Number:	15/106,783
Patent Claims:	1. A method for treating cancer in a patient in need thereof comprising administering to said patient an immune cell comprising a multi-chain chimeric antigen receptor (CAR) comprising: an extracellular ligand binding domain capable of recognizing a specific ligand expressed at the surface of a tumor cell, said extracellular ligand binding domain further comprising a hinge selected from CD8.beta., CD4, CD28, RTK, IgGI, and EpoR2-D2; a transmembrane domain; an intracellular domain comprising a CD3.zeta. domain; and an oxygen-sensitive polypeptide domain, wherein said multi-chain CAR comprises part of the alpha, beta, and gamma chains from an Fc receptor comprising an amino acid sequence identity greater than 80% to SEQ ID NO: 7, 3 and 4, respectively. 2. The method of claim 1, wherein the multi-chain CAR comprises: part of an alpha-chain comprising a CD8 hinge region as an extracellular domain, an FcR.alpha. as a transmembrane domain, and a part of FcR.alpha. combined with HIF-I.alpha. or HIF-3.alpha. subunit as an intracellular domain; part of a beta-chain comprising an FcR.beta. as an extracellular domain, a FcR.beta. transmembrane domain, and a 4-1BB as an intracellular co-stimulation domain; and part of a gamma-chain comprising an FcR.gamma. transmembrane domain, and a CD3 as a intracellular activation domain. 3. The method according to claim 1, wherein the cancer is a solid tumor. 4. The method according to claim 1, wherein said oxygen-sensitive domain is HIF-I.alpha., HIF-3.alpha., or an amino acid sequence comprising an amino acid sequence identity greater than 80% to SEQ ID NO: 22, 23, 85, or SEQ ID NO:26, 27. 5. The method according to claim 1, wherein said hinge is a CD8a, IgG1 or EpoR-D2 hinge. 6. The method according to claim 1, wherein said extracellular binding domain comprises a scFv directed to an epitope of a cell target antigen EGFRvIII, CS1, CT83, GD3, MSCP, CD19, 5T4, CD123, CD33, CD20, CD30, CD40, disialoganglioside GD2, C-type lectin-like molecule-1 (CLL-1), ductal-epithelial mucine, gp36, TAG-72, glycosphingolipids, glioma-associated antigen, 13-human chorionic gonadotropin, alphafetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxyl esterase, mut hsp70-2, M-CSF, prostase, prostaste specific antigen (PSA), PAP, NY-ESO-1, LAGA-Ia, p53, protein, PSMA, surviving and telomerase, prostate-carcinoma tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22, insulin growth factor (IGF1)-I, IGF-II, IGFI receptor, mesothelin, a major histocompatibility complex (MHC) molecule presenting a tumor-specific peptide epitope, 514, ROR1, Nkp30, NKG2D, tumor stromal antigens, the extra domain A (EDA) and extra domain B (EDB) of fibronectin and the AI domain of tenascin-C (TnC AI) and fibroblast associated protein (fap), LRP6, melamona-associated Chondroitin Sulfate Proteoglycan (MCSP), CD38/CS1, MART1, WT1, MUC1, LMP2, Idiotype, NY-ESO-1, Ras mutant, gp100, proteinase 3, bcr-abl, tyrosinase, hTERT, EphA2, ML-TAP, ERG, NA17, PAX3, ALK, Androgen receptor; a lineage-specific or tissue specific antigen such as CD3, CD4, CD8, CD24, CD25, CD34, CD79, CD116, CD117, CD135, CD123, CD133, CD138, CTLA-4, B7-1 (CD80), B7-2 (CD86), endoglin, a major histocompatibility complex (MHC) molecule, BCMA (CD269, TNFRSF 17), or a virus-specific surface antigen such as an HIV-specific antigen (such as HIV 120), an EBV-specific antigen, a CMV-specific antigen, a HPV-specific antigen, a Lasse Virus-specific antigen, or an Influenza Virus-specific antigen. 7. The method according to claim 1, wherein said extracellular binding domain comprises a scFv having a polypeptide sequence comprising an amino acid sequence identity greater than 80% to SEQ ID NO: 32, 35, 38; SEQ ID NO: 33; SEQ ID NO:34; SEQ ID NO:36 or SEQ ID NO:37. 8. The method according to claim 1, wherein said intracellular domain comprises a linker of a CD3 domain. 9. The method according to claim 1, wherein the CAR further comprises a co-stimulation domain of 4-1BB or CD28.

Details for Patent 10,239,948

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2034-12-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2034-12-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2034-12-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2034-12-19
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974		2034-12-19
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973		2034-12-19